ERBB2 and breast carcinoma: MDA-MB-453 breast cancer cells used in this work were resistant to the antiproliferative activity of trastuzumab in vitro (our unpublished results and [34]), therefore the results shown here modeled a relevant clinical situation in which HER-2+ breast cancer progressed in the brain and other organs after anti-HER-2 monoclonal antibody therapy.